{"id":"nsaid-aceclofenac","safety":{"commonSideEffects":[{"rate":"10–20","effect":"Gastrointestinal disorders (dyspepsia, abdominal pain, nausea)"},{"rate":"5–10","effect":"Headache"},{"rate":"2–5","effect":"Dizziness"},{"rate":"1–3","effect":"Rash"},{"rate":"1–3","effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a nonsteroidal anti-inflammatory drug (NSAID), aceclofenac preferentially inhibits COX-2 while also affecting COX-1, suppressing the production of pro-inflammatory prostaglandins. This mechanism reduces pain, inflammation, and fever. Aceclofenac is a prodrug that is metabolized to diclofenac, which accounts for much of its pharmacological activity.","oneSentence":"Aceclofenac inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:41:49.670Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Osteoarthritis"},{"name":"Ankylosing spondylitis"},{"name":"Acute pain and inflammation"}]},"trialDetails":[{"nctId":"NCT05980572","phase":"NA","title":"Effects of App-assisted Home Exercise Program in Patients With Frozen Shoulder","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2022-09-11","conditions":"Frozen Shoulder","enrollment":21},{"nctId":"NCT05237297","phase":"PHASE1","title":"Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Naproxen, Aceclofenac, Celecoxib and Ilaprazole","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2022-02-17","conditions":"Drug Interaction Potentiation","enrollment":72},{"nctId":"NCT02883569","phase":"NA","title":"Comparative Effectiveness Study for Surgery vs. Non-Surgery in Patients With Low Back Pain","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2016-09","conditions":"Low Back Pain","enrollment":1102},{"nctId":"NCT01912066","phase":"PHASE4","title":"A Multicenter, Double Blinded, Randomized, Parallel Assignment Study to Demonstrate the Efficacy of DA9601","status":"COMPLETED","sponsor":"Dong-A ST Co., Ltd.","startDate":"2012-09","conditions":"NSAID-associated Gastroduodenal Injury","enrollment":520},{"nctId":"NCT00635349","phase":"PHASE4","title":"A Comparative Study of Tramadol Hydrochloride Plus Acetaminophen Tablets Maintenance Versus Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Maintenance in Participants With Knee Osteoarthritis","status":"COMPLETED","sponsor":"Janssen Korea, Ltd., Korea","startDate":"2007-05","conditions":"Osteoarthritis","enrollment":143}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":429,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"NSAID (Aceclofenac)","genericName":"NSAID (Aceclofenac)","companyName":"Dong-A ST Co., Ltd.","companyId":"dong-a-st-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aceclofenac inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain. Used for Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}